For decades, Christopher Bunick and his colleagues at Yale School of Medicine have watched patients pop doxycycline for everything from acne to Lyme disease—11 million prescriptions every single year—without truly understanding how the drug actually kills bacteria. That changed on May 19, when Bunick's team published a breakthrough study in Nature Communications that reveals, for the first time, how tetracyclines bind to not one but two critical sites on bacterial ribosomes.
The discovery matters profoundly because antibiotic resistance is one of modern medicine's defining challenges. If scientists can understand exactly how these 70-year-old drugs work at the molecular level, they can engineer smarter versions: antibiotics that are more potent against dangerous bacteria, kinder to the gut microbiome, and harder for resistance to evolve against.
Using a technique called single particle cryo-electron microscopy (cryo-EM), the Yale researchers visualized how three common tetracyclines—doxycycline, sarecycline, and minocycline—interact with the ribosomes of two bacteria: Escherichia coli, which colonizes the gut, and Cutibacterium acnes, which causes acne. The results overturned a half-century of textbook knowledge. Scientists had long known that tetracyclines block the mRNA decoding center, a region where bacteria assemble proteins. But the Yale team discovered that doxycycline does something far more clever: it binds to a second site on the ribosome, the nascent peptide exit tunnel (NPET)—the narrow passage where newly made proteins squeeze out.
Here is where the chemistry becomes elegant. Unlike most antibiotics, which bind as single molecules, doxycycline can pair with itself, forming dimers that sit snugly in the NPET and block it more effectively. "Every year, there are around 11 million prescriptions for doxycycline, and yet, for decades, people didn't know how it was working," said Swapnil Chandrakant Devarkar, co-first author of the study. "Our study provides a structural and mechanistic basis for why this one drug works so well."
The second revelation concerns sarecycline, an FDA-approved acne treatment introduced in 2018. Unlike doxycycline, sarecycline targets gram-positive bacteria like C. acnes while largely sparing gram-negative organisms in the gut microbiome. This narrow spectrum is why it causes fewer gastrointestinal side effects—but nobody understood why it worked that way. The Yale team's imaging revealed the answer: sarecycline's bulkier molecular structure means it cannot fit neatly into the NPET of E. coli. The drug must flip 180 degrees to fit at all, and often fails to bind entirely. This selectivity allows sarecycline to kill acne-causing bacteria while leaving beneficial gut flora untouched.
These structural insights point toward a future of rationally designed antibiotics. Ivan Lomakin, the study's corresponding author, suggests that tetracyclines engineered to dimerize like doxycycline—but with sarecycline's selective binding—could yield antibiotics that are simultaneously more potent and more microbiome-friendly. In an era when antibiotic resistance spreads faster than new drugs arrive, this marriage of old chemistry and new imaging technology offers a real path forward.